Floatz logo

cgt4859

Advanced Solid Tumors

Cogent Biosciences, Inc.Phase 1/2Active
CC
40/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
59/ 100

Competitive context

1411 Active assets in the Advanced Solid Tumors cohort.

Asset / SponsorPhaseRating
Nabiximols
Jazz Pharmaceuticals
Phase 3BBB
Inno-206
M.D. Anderson Cancer Center
Phase 2BB
Vitamin B6
M.D. Anderson Cancer Center
Phase 4BB
PROPOFOL
Hong Kong Children's Hospital
Phase 4BB
Rivoceranib
Jiangsu HengRui Medicine Co., Ltd.
Phase 4BB

View all 50 →

Same molecule, other indications

cgt4859 is also rated in:

FGFR2 Gene Fusion/RearrangementDormant
CCC
Indicative ·
48 / 100
View asset →
Other Solid Tumors, AdultDormant
CCC
Indicative ·
48 / 100
View asset →
FGFR2 Gene AmplificationDormant
CCC
Indicative ·
48 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →